Price Chart

Profile

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate,  Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
URL https://www.igmbio.com
Investor Relations URL https://investor.igmbio.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Mar. 07, 2025 (est.)
Last Earnings Release Nov. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate,  Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
URL https://www.igmbio.com
Investor Relations URL https://investor.igmbio.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Mar. 07, 2025 (est.)
Last Earnings Release Nov. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A